Assetmark Inc. Boosts Holdings in Becton, Dickinson and Company $BDX

Key Points

• Assetmark Inc. increased its stake in Becton, Dickinson and Company by 19.9% in Q4 to 270,910 shares, worth about $52.6 million (approximately 0.10% of the company).
• BDX reported Q results with EPS of $2.91 (beating estimates by $0.10) while revenue missed at $4.49B versus $5.15B; management set FY2026 guidance of 12.350–12.650 EPS and analysts hold a consensus "Hold" rating with an average target of $189.92.
• The board approved a $10 million share buyback and the company pays a quarterly dividend of $1.05 (annualized $4.20, yield 2.7%), while insiders sold 2,713 shares totaling about $536,881 over the last three months.

Assetmark Inc. raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 19.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 270,910 shares of the medical instruments supplier's stock after acquiring an additional 44,943 shares during the quarter. Assetmark Inc. owned approximately 0.10% of Becton, Dickinson and Company worth $52,575,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Activest Wealth Management increased its holdings in Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock valued at $25,000 after acquiring an additional 97 shares in the last quarter. Imprint Wealth LLC purchased a new position in Becton, Dickinson and Company during the 3rd quarter valued at about $25,000. SOA Wealth Advisors LLC. increased its holdings in Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier's stock valued at $25,000 after acquiring an additional 95 shares in the last quarter. Steph & Co. boosted its stake in shares of Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 65 shares during the last quarter. Finally, Accredited Wealth Management LLC boosted its stake in shares of Becton, Dickinson and Company by 77.8% during the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 70 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 953 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director owned 36,763 shares of the company's stock, valued at $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the firm's stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 2,713 shares of company stock worth $536,881 over the last three months. Corporate insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Price Performance

BDX opened at $155.72 on Wednesday. The company's 50 day simple moving average is $169.00 and its 200 day simple moving average is $184.98. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The stock has a market capitalization of $44.34 billion, a PE ratio of 25.40, a P/E/G ratio of 11.06 and a beta of 0.29.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business had revenue of $4.49 billion for the quarter, compared to analysts' expectations of $5.15 billion. During the same period last year, the company earned $3.43 earnings per share. The company's quarterly revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share buyback plan on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's management believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th were given a $1.05 dividend. The ex-dividend date of this dividend was Tuesday, March 10th. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 68.52%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Argus decreased their price target on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a "buy" rating on the stock in a research note on Monday, March 23rd. Wells Fargo & Company decreased their price target on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 10th. Barclays assumed coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. They set an "overweight" rating and a $202.00 price target on the stock. TD Cowen raised their price target on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a "hold" rating in a research note on Wednesday, February 11th. Finally, The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a research note on Friday. They set a "neutral" rating and a $167.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $189.92.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.